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Several studies support reciprocal regulation between the active vitamin D derivative 1𝛼,25-dihydroxyvitamin D
3
(1,25(OH)
2
D
3
)
and the epithelial to mesenchymal transition (EMT). Thus, 1,25(OH)
2
D
3
inhibits EMT via the induction of a variety of target
genes that encode cell adhesion and polarity proteins responsible for the epithelial phenotype and through the repression of key
EMT inducers. Both direct and indirect regulatory mechanisms mediate these effects. Conversely, certain master EMT inducers
inhibit 1,25(OH)
2
D
3
action by repressing the transcription of𝑉𝐷𝑅 gene encoding the high affinity vitaminD receptor thatmediates
1,25(OH)
2
D
3
effects. Consequently, the balance between the strength of 1,25(OH)
2
D
3
signaling and the induction of EMT defines
the cellular phenotype in each context. Here we review the current understanding of the genes and mechanisms involved in the
interplay between 1,25(OH)
2
D
3
and EMT.
1. The Vitamin D System
The mammalian form of vitamin D is the prohormone
vitamin D
3
(cholecalciferol), which is obtained from the diet
or mainly synthesized in the skin from 7-dehydrocholesterol
through ultraviolet B radiation. Vitamin D
3
is hydroxylated,
first in the liver and then in the kidney and other tis-
sues, to generate 1𝛼,25-dihydroxyvitamin D
3
(1,25(OH)
2
D
3
,
calcitriol), the most active vitamin D
3
metabolite [1–5].
1,25(OH)
2
D
3
is a major regulator of gene expression and
exerts its effects by binding to a transcription factor of the
nuclear receptor superfamily: the vitamin D receptor (VDR).
VDR heterodimerizes with another member of the same
family, the retinoid X receptor, and regulates gene expression
in a ligand-dependent manner. The prevailing model holds
that in the absence of 1,25(OH)
2
D
3
the heterodimer is
bound to specific sequences on its target genes (vitamin
D response elements) and to transcriptional corepressors
that recruit complexes with histone deacetylase activity, thus
maintaining the chromatin in a transcriptionally repressed
state. 1,25(OH)
2
D
3
induces conformational changes in VDR
that cause the release of corepressors and the binding of coac-
tivators and chromatin remodelers. Together they mediate
chromatin opening and permit the entry of the basal RNA
polymerase II transcription machinery and transcription
initiation [1, 6–9].
1,25(OH)
2
D
3
is a pleiotropic hormone with many regu-
latory effects. It was classically known for its action on cal-
cium and phosphorus homeostasis and bone mineralization
[2, 10]. The seminal discoveries in 1981 that 1,25(OH)
2
D
3
induced myeloid leukemia cell differentiation and inhib-
ited melanoma cell proliferation prompted the interest in
1,25(OH)
2
D
3
as an anticancer agent [11, 12]. Subsequent
observations have shown that 1,25(OH)
2
D
3
induces differ-
entiation and apoptosis and inhibits proliferation, migra-
tion, invasion, and angiogenesis in cancer cells of different
origin and in several animal models of cancer [1, 5, 13–
16]. However, the administration of 1,25(OH)
2
D
3
to cancer
patients is restricted by its hypercalcemic effects at the
therapeutic doses, enforcing the development of several
analogs that maintain the antitumoral properties but have
less calcemic actions. Currently, numerous clinical trials
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are ongoing using 1,25(OH)
2
D
3
or its analogs, alone or in
combination with other anticancer agents, against several
neoplasms (https://www.clinicaltrials.gov/) [1, 4, 5, 13].
2. Epithelial to Mesenchymal Transition
Epithelial to mesenchymal transition (EMT) is the process
by which epithelial cells are converted into mesenchymal
cells. It takes place physiologically in several developmental
situations such as mesoderm formation and neural crest
migration. In the adult, it is reactivated in certain pathological
conditions such as wound healing, fibrosis, and cancer pro-
gression [17, 18].During EMT, epithelial cells lose cell-cell and
cell-extracellular matrix junctions, change from an apical-
basal to a front-rear polarity, reorganize their cytoskeleton,
and undergo a gene expression reprogramming characterized
by the downregulation of the epithelial gene signature and
the activation of mesenchymal genes. This process generates
motile individual cells that can degrade the extracellular
matrix and thus develop a migratory and invasive phenotype
[18–21]. EMT is a highly regulated, plastic, and reversible
process. Thus, the mesenchymal to epithelial transition
(MET) occurs under certain conditions and enables that
mesenchymal cells acquire an epithelial state [22–25].
Typical EMT gene reprogramming is mainly orches-
trated by key transcription factors including the zinc finger
proteins SNAIL1 and SNAIL2, the double zinc finger and
homeodomain factors ZEB1 and ZEB2, and the members
of the basic-helix-loop-helix family TWIST1 and E47, all
known as EMT transcription factors (EMT-TFs). They are
repressors of E-cadherin (encoded by CDH1), that is the
main component of adherens junctions and essential for the
maintenance of the epithelial state. Thus, E-cadherin down-
regulation is considered a hallmark of EMT. In addition to the
established EMT inducers, other transcription factors such as
FOXC2, Goosecoid, KLF8, TCF4 (also known as E2-2), SIX1,
HMGA2, Brachyury, and PRRX1 have been recently shown
to induce or regulate EMT [18–21, 24]. Expression and/or
activity of the transcription factors that drive EMT is induced
and controlled by several signaling pathways that respond
to extracellular cues, with a prominent role for transforming
growth factor- (TGF-) 𝛽 signaling. The contribution of each
transcription factor to the EMT depends on the cell or tissue
type involved and the signaling pathway that initiates the
EMT. Moreover, EMT-TFs often exhibit reciprocal control of
their expressions and functional cooperation [18–20, 22, 23].
3. 1,25(OH)
2
D
3
Inhibits EMT
3.1. 1,25(OH)2D3 Induces the Expression of Epithelial Markers.
1,25(OH)
2
D
3
induces epithelial differentiation in several nor-
mal and cancer cells. Accordingly, it increases the expression
of components of almost all types of cell adhesion structures
that are essential for the acquisition and maintenance of
the epithelial phenotype (Table 1). Remarkably, we found
that the strong prodifferentiation effect of 1,25(OH)
2
D
3
in
human colon cancer cells is associated with an increase in the
expression of the key adhesion molecule E-cadherin. This is
accompanied by the redistribution of 𝛽-catenin from the cell
nucleus to the adherens junctions at the plasma membrane
where it interacts with E-cadherin, thus inhibiting theWnt/𝛽-
catenin signaling pathway that is aberrantly activated in
most colon tumors and required for colon carcinogenesis
[26]. In human colon cancer cells, 1,25(OH)
2
D
3
also induces
the expression of the tight junction components occludin,
claudin-1, claudin-2, claudin-7, claudin-12, zonula occludens-
(ZO-) 1 and ZO-2, the desmosomal protein plectin, the focal
adhesion members integrin 𝛼
3
and paxillin, the constituent
of intermediate filaments keratin-13, and proteins associated
with the actin cytoskeleton such as vinculin, filamin A,
and ezrin [26, 27, 29–31, 49, 50]. Interestingly, 1,25(OH)
2
D
3
downregulates cadherin-17 [72], which induces cell prolifer-
ation and has protumoral and prometastatic effects in colon
cancer cells [73].
Treatment of the 𝐴𝑝𝑐min/+ colon cancer mouse model
with 1,25(OH)
2
D
3
or analogs reduces polyp number and
load, while it increases E-cadherin levels and reduces 𝛽-
catenin nuclear localization and the expression of the 𝛽-
catenin target genesTcf1,Myc, andCd44 in the small intestine
and colon [32]. Conversely, 𝑉𝑑𝑟 deficiency in 𝐴𝑝𝑐min/+ mice
enhances tumor size and the activity of the Wnt/𝛽-catenin
pathway in the lesions [65, 74]. Similar results were observed
in other mouse and rat models of colon dysplasia, colon
cancer, and colitis-associated neoplasia when treated with
vitamin D
3
or 1,25(OH)
2
D
3
analogs [33, 63, 64]. Moreover,
1,25(OH)
2
D
3
increases and restores the normal level of Zo-
1, occludin, and claudin-1 proteins in the colonic epithelium
of the dextran sulfate sodium- (DSS-) induced colitis mouse
model, protecting mice from intestinal mucosa injury and
epithelial barrier disruption [27]. Conversely, 𝑉𝑑𝑟 deficiency
potentiates DSS effects in this model, as DSS-treated 𝑉𝑑𝑟−/−
mice have severely disrupted and opened tight junctions and
desmosomes in the colonic epithelium and develop more
severe colitis than wild-type animals [29].These data indicate
that 1,25(OH)
2
D
3
contributes to the homeostasis and healing
capacity of the colonic epithelium by preserving the stability
and structural integrity of tight junctions [75]. Remarkably,
a randomized, double-blind, placebo-controlled clinical trial
showed that daily treatment of colorectal adenoma patients
with 800 IU of vitamin D
3
for 6 months increases E-cadherin
expression in normal-appearing rectal mucosa [34, 76].
In addition to colon cancer, E-cadherin is induced by
1,25(OH)
2
D
3
or analogs in normal mammary and bronchial
epithelial cells and in tumor cell lines derived from breast,
prostate, non-small cell lung, and squamous cell carcinomas,
usually associated with an increase in epithelial differen-
tiation, a reduction in cell migration and invasion, and
the inhibition of Wnt/𝛽-catenin signaling [35–41, 61, 77,
78]. We have described that the mechanism of E-cadherin
induction by 1,25(OH)
2
D
3
in human colon cancer cells is
transcriptional indirect and requires the transient activation
of the RhoA-ROCK-p38MAPK-MSK1 signaling pathway [26,
31]. Phosphatidylinositol 5-phosphate 4-kinase type II 𝛽 is
also needed for E-cadherin induction by 1,25(OH)
2
D
3
in
colon cancer cells [79]. In agreement with the transcriptional
regulation, Lopes et al. showed that 1,25(OH)
2
D
3
treatment
causes partial demethylation of CpG sites of CDH1 promoter
in MDA-MB-231 triple-negative breast cancer cells [78].
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Table 1: List of 1,25(OH)
2
D
3
-regulated proteins involved in EMT.
Protein 1,25(OH)
2
D
3
effect Reference
Tight junction components
Occludin Upregulation [26–28]
Claudin-1 Upregulation [27, 29]
Claudin-2 Upregulation [29, 30]
Claudin-7 Upregulation [31]
Claudin-12 Upregulation [30]
ZO-1 Upregulation [26, 27, 29]
ZO-2 Upregulation [26]
Adherens junction proteins
E-cadherin Upregulation [26, 29, 31–46]
N-cadherin Downregulation [37, 41, 42, 47, 48]
P-cadherin Downregulation [37]
Vinculin Upregulation [26, 31]
Focal adhesion members
Integrin 𝛼
3
Upregulation [31]
Integrin 𝛼V Upregulation [37]
Integrin 𝛽
5
Upregulation [37]
Integrin 𝛼
6
Downregulation [37]
Integrin 𝛽
4
Downregulation [37]
Paxillin Upregulation [31, 37]
FAK Upregulation [37]
Cytoskeleton-related proteins
Filamin A Upregulation [49]
Ezrin Upregulation [50]
𝛼-SMA Downregulation [37, 43–46, 51–54]
Keratin-13 Upregulation [49]
Vimentin Downregulation [40–42]
Plectin Upregulation [49]
Extracellular matrix proteins
Fibronectin Downregulation [44, 45, 51, 54]
Collagen type I Downregulation [44, 45, 51, 53–57]
Collagen type II Downregulation [56]
Collagen type III Downregulation [44, 51, 54, 58]
MMPs and inhibitors
MMP2 Downregulation [39, 41, 42]
MMP9 Downregulation [39, 41, 42, 59, 60]
MMP13 Downregulation [48, 61]
TIMP1 Upregulation [59, 60]
TIMP2 Upregulation [59]
EMT-TFs
SNAIL1 Downregulation [40–42, 44, 61, 62]
SNAIL2 Downregulation [42, 61, 62]
ZEB1 Downregulation [40]
TWIST1 Downregulation [61]
Wnt/𝛽-catenin target genes
MYC Downregulation [26, 32, 63, 64]
TCF1 Downregulation [26, 32]
CD44 Downregulation [26, 32]
Cyclin D1 Downregulation [31, 33, 55, 64]
Table 1: Continued.
Protein 1,25(OH)
2
D
3
effect Reference
AXIN2 Downregulation [65]
LEF1 Downregulation [65]
Other EMT-related proteins
JMJD3 Upregulation [66]
Cystatin D Upregulation [67]
Cathepsin L Downregulation [68]
Sprouty-2 Downregulation [69]
PIT1 Downregulation [70]
IL-1𝛽 Downregulation [71]
TGF-𝛽 Downregulation [44, 54, 56, 58]
TGF-𝛽 receptor type I Downregulation [44]
Cadherin-17 Downregulation [72]
Moreover, protein kinase C inhibitors block E-cadherin, P-
cadherin, 𝛼-catenin, and vinculin translocation to cell-cell
contacts and the assembly of adherens junctions promoted
by 1,25(OH)
2
D
3
in cultured human keratinocytes [80].
We reported that 1,25(OH)
2
D
3
induces cell adhesion,
inhibits cell migration and invasion, and profoundly affects
the phenotype of human breast cancer cells [37]. It promotes
the formation of focal adhesions by increasing the expression
of integrin 𝛼V, integrin𝛽5, paxillin, and focal adhesion kinase
(FAK) proteins and also by inducing FAK phosphorylation.
Additionally, 1,25(OH)
2
D
3
reduces the expression of themes-
enchymal marker N-cadherin and the myoepithelial proteins
P-cadherin, integrin 𝛼
6
, integrin 𝛽
4
, and 𝛼-smooth muscle
actin (𝛼-SMA). Thus, 1,25(OH)
2
D
3
reverts the myoepithelial
features that are associated with more aggressive and lethal
forms of human breast cancer [37]. Likewise, N-cadherin
expression is strongly suppressed by 1,25(OH)
2
D
3
in mouse
osteoblast-like cells [47]. In line with these data, 1,25(OH)
2
D
3
treatment blocks the EMT-associated cadherin switch (from
E-cadherin to N-cadherin) in pancreatic cancer cells [42].
Notably, 1,25(OH)
2
D
3
enhances corneal epithelial barrier
function as corneal epithelial cells treated with 1,25(OH)
2
D
3
show increased occludin levels, reduced permeability, and
elevated transepithelial resistance, a measure of the func-
tional integrity of tight junctions [28].
3.2. 1,25(OH)2D3 Inhibits the Expression of EMT-TFs. We
and others have reported that 1,25(OH)
2
D
3
regulates the
expression of certain transcription factors that induce EMT
andof severalmodulatorsof theepithelial phenotype that can in
fluencetheexpressionoftheEMTinducers(Table 1). 1,25(OH)
2
D
3
increases by a transcriptional indirectmechanism the expres-
sion of Jumonji Domain Containing 3 (JMJD3), a histone
H3 lysine 27 demethylase with putative tumor suppressor
activity. JMJD3 mediates the induction of a highly adhesive
epithelial phenotype, the antiproliferative effect, the gene
regulatory action, and the antagonism of the Wnt/𝛽-catenin
pathway promoted by 1,25(OH)
2
D
3
in human colon cancer
cells [66]. Moreover, JMJD3 depletion upregulates SNAIL1,
ZEB1, and ZEB2, increases the expression of the mes-
enchymal markers fibronectin and LEF1, and downregulates
4 Stem Cells International
the epithelial proteins E-cadherin, claudin-1, and claudin-7.
Accordingly, JMJD3 and SNAIL1 RNA expression correlate
inversely in samples from human colon cancer patients [66].
The induction of ZEB1 by JMJD3 depletion is associated
with the downregulation of miR-200b and miR-200c, two
microRNAs that target ZEB1 RNA and inhibit ZEB1 protein
expression [81].
1,25(OH)
2
D
3
directly induces the expression of cystatin
D, an inhibitor of cysteine proteases of the cathepsin fam-
ily encoded by CST5 gene. The binding of VDR to the
CST5 promoter induced by 1,25(OH)
2
D
3
is accompanied
by the release of the NCOR2 corepressor and an increase
in histone H4 acetylation [67]. We found that cystatin D
mediates the antiproliferative and prodifferentiation action
of 1,25(OH)
2
D
3
in human colon cancer cells. In addition,
ectopic cystatin D expression inhibits proliferation, migra-
tion, anchorage-independent growth, and theWnt/𝛽-catenin
pathway in cultured colon cancer cells and reduces tumor
development in xenografted mice [67]. Cystatin D represses
SNAIL1, SNAIL2, ZEB1, and ZEB2, whereas it induces the
expression of E-cadherin and other adhesion proteins such
as occludin and p120-catenin. Accordingly, cystatin D and
E-cadherin protein expression directly correlate in human
colorectal cancer, and loss of cystatin D is associated with
poor tumor differentiation [67]. Notably, transcriptomic and
proteomic studies comparing cystatin D-overexpressing and
mock-transfected human colon cancer cells indicated that
“cell adhesion, cell junction, and cytoskeleton” is one of
the gene categories that englobes more cystatin D-regulated
genes and proteins [82]. Remarkably, Swami et al. showed
that the expression of cathepsin L, whose activity is inhibited
by cystatin D, is downregulated by 1,25(OH)
2
D
3
in breast
cancer cells [68], while Zhang et al. described that silencing
of cathepsin L suppresses the cell invasion andmigration, the
actin cytoskeleton remodeling, and the increase in SNAIL1
expression associated with TGF-𝛽-promoted EMT in breast
and lung cancer cells [83].
1,25(OH)
2
D
3
reducesthe expression of Sprouty-2, an intra-
cellular modulator of growth factor tyrosine kinase receptor
signaling involved in the regulation of cell growth, migra-
tion, and angiogenesis [69]. Sprouty-2 strongly inhibits the
induction of intercellular adhesion and E-cadherin protein
expression promoted by 1,25(OH)
2
D
3
, and gain- and loss-of-
function experiments indicate that Sprouty-2 and E-cadherin
repress each other in colon cancer cells. Accordingly, the
protein expression levels of Sprouty-2 and E-cadherin corre-
late inversely in cultured and xenografted colon cancer cells
and in biopsies from human colon cancer patients. In line
with this, we found that Sprouty-2 induces ZEB1 expression
without affecting ZEB2, SNAIL1, or SNAIL2 levels [69]. ZEB1
upregulation by Sprouty-2 results from the induction of
the transcription factor ETS1 and the repression of several
microRNAs (miR-200 family and miR-150) that target ZEB1
RNA. Through ZEB1 upregulation, Sprouty-2 represses E-
cadherin, claudin-7, occludin, the tight junction modulator
matriptase, the cell adhesion molecule EPCAM, and the
epithelial splicing regulatory protein ESRP1 that inhibits EMT
[84]. Taken together, these data point to Sprouty-2 as a potent
inhibitor of the epithelial phenotype that is downregulated by
1,25(OH)
2
D
3
in colon carcinoma cells.
Recently, effects of 1,25(OH)
2
D
3
on the expression of
several EMT-TFs have been described. 1,25(OH)
2
D
3
inhibits
SNAIL1 and ZEB1 expression in non-small cell lung carci-
noma cells, accompanied by an increase in E-cadherin expres-
sion, vimentin downregulation, maintenance of the epithelial
morphology, and inhibition of cell migration [40]. The low
calcemic 1,25(OH)
2
D
3
analog MART-10 inhibits EMT and
cell migration and invasion in breast and pancreatic cancer
cells through the downregulation of SNAIL1 and SNAIL2.
In addition, MART-10 inhibits TWIST1 expression in breast
cancer cells [42, 61]. Accordingly, Findlay et al. reported the
inhibition of SNAIL1 and SNAIL2 by 1,25(OH)
2
D
3
in human
colon cancer cells [62]. Kaler et al. found that colon can-
cer cells stimulate tumor-associated macrophages to secrete
interleukin- (IL-) 1𝛽, which in turn promotes Wnt/𝛽-catenin
signaling, stabilizes SNAIL1 protein, and confers resistance to
TRAIL-induced apoptosis in colon cancer cells [71].They also
found that 1,25(OH)
2
D
3
, by inhibiting the release of IL-1𝛽
by macrophages, downregulates SNAIL1 protein expression
in colon cancer cells [71]. Similarly, Zhang et al. showed that
tumor-associated macrophages induce EMT in breast cancer
cells and that high VDR expression in cancer cells abrogates
the macrophage-promoted E-cadherin loss, 𝛼-SMA upreg-
ulation, and increase in cell migration and invasion [43].
Furthermore, 1,25(OH)
2
D
3
attenuates the enhancing effect
of TGF-𝛽1 on cell motility and on SNAIL1, N-cadherin, and
vimentin expression in human bronchial epithelial cells [41]
and inhibits theTGF-𝛽1-stimulatedEMT in rat lung epithelial
cells [51].
Matrix metalloproteases (MMPs) are a family of zinc-
dependent proteases that degrade components of the extra-
cellular matrix and basement membrane. MMPs are regu-
lated by the action of specific inhibitors: the tissue inhibitors
ofmetalloproteases (TIMPs). IncreasedMMPactivity is often
associated with the EMT and confers invasive properties to
cancer cells. Consistently with its inhibitory effect on EMT,
1,25(OH)
2
D
3
downregulates the secretion of MMP2, MMP9,
and MMP13 in prostate, breast, pancreatic, and squamous
cell carcinoma cells and increases TIMP1 and TIMP2 activity
in prostate and breast cancer cells [39, 42, 48, 59–61]. In
addition, 1,25(OH)
2
D
3
reduces the increase in MMP2 and
MMP9 induced by TGF-𝛽1 in human bronchial epithelial
cells [41]. Through these mechanisms, 1,25(OH)
2
D
3
inhibits
the capacity of cancer cells to degrade the extracellularmatrix
and invade the surrounding tissue and may thus reduce
tumor cell metastatic potential. Remarkably, several stud-
ies from Pe´rez-Ferna´ndez’s group have demonstrated that
1,25(OH)
2
D
3
represses the expression of the gene encoding
the pituitary transcription factor 1 (PIT1) in breast cancer cells
and that PIT1 silencing downregulates SNAIL1, MMP1, and
MMP13 proteins [70, 85, 86]. In agreement with this, high
PIT1 protein expression correlates with elevated MMP1 and
MMP13 levels, SNAIL1 protein expression, and presence of
distant metastasis in invasive ductal breast carcinoma [85,
86].
Recent studies have established a link between the
induction of EMT and the acquisition by epithelial cells of
molecular and functional traits of stem cells. As stem cells
can both self-renew and differentiate, these stemness-related
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properties confer tumor-initiating capacities to carcinoma
cells that could be crucial for cancer cell survival during
dissemination and for the establishment by the disseminated
cancer cells ofmetastatic foci at anatomically distant sites [19–
25]. Interestingly, Pervin et al. found that manipulation of
VDR levelsmodulates the expression of key EMT-related pro-
teins and dictates the stem cell characteristics of breast cancer
cells. Thus, 𝑉𝐷𝑅 overexpression in these cells upregulates
E-cadherin, downregulates SNAIL1, TWIST1, and MMP9,
and reduces cell ability to form mammospheres, an attribute
of breast normal and cancer stem cells. Conversely, 𝑉𝐷𝑅
silencing has the opposite effect [87].
3.3. 1,25(OH)2D3 Inhibits Fibrosis. In addition to cancer
progression, EMT is reactivated in adult life during other
pathological processes such as organ fibrosis. This process
occurs in certain epithelial tissues after trauma or inflamma-
tory injury and is characterized by excessive deposition of
extracellular matrix and increased fibrous connective tissue.
In this context, the EMT is part of the repair program
and originates fibroblasts and other related cells for tissue
regeneration. However, the disease usually progresses and
the organ is finally composed mainly of activated fibroblasts
and extracellular matrix, which may eventually lead to organ
failure. The EMT inducer TGF-𝛽 is also involved in the
fibrotic process [17, 23, 88]. Several studies from Liu’s group
showed that vitaminD compounds attenuate renal interstitial
fibrosis by inhibiting EMT in tubular epithelial cells. These
compounds decrease collagen and fibronectin deposition,
downregulate the expression of SNAIL1, 𝛼-Sma, 𝛽-catenin,
TGF-𝛽1, and its type I receptor, reduce 𝛽-catenin nuclear
localization, and preserve Vdr and E-cadherin levels in
kidneys from an obstructive nephropathy mouse model that
develops interstitial fibrosis. Moreover, treatment with vita-
min D compounds or 𝑉𝐷𝑅 overexpression in human renal
proximal tubular epithelial cells abolishes the EMT promoted
by TGF-𝛽1, while 𝑉𝐷𝑅 silencing has a sensitizing effect [44,
45, 89]. Interestingly, combination of the 1,25(OH)
2
D
3
analog
paricalcitol with trandolapril, an inhibitor of the angiotensin-
converting enzyme used as standard treatment for chronic
kidney disease, leads to additive reduction of renal fibrosis in
the obstructive nephropathymousemodel [90]. Additionally,
Nolan et al. indicated that paricalcitol inhibits TGF-𝛽1-
induced tubular EMT also under the hypoxic conditions
commonly associated with chronic kidney disease [46], and
Kim et al. reported that it attenuates the tubular EMT
exogenously induced by 4-hydroxy-2-hexenal, an aldehyde
product of lipid peroxidation [52].
Beneficial effects of 1,25(OH)
2
D
3
have also been reported
in liver fibrosis. Hepatic stellate cells play a central role in liver
fibrosis as upon injury-induced activation they proliferate
and secrete many extracellular matrix components. Vitamin
D compounds reduce extracellular matrix deposition and
ameliorate liver fibrosis in rat and mouse models [55, 56].
In addition, 1,25(OH)
2
D
3
suppresses cell proliferation and
downregulates cyclin D1 and 𝛼
1
type I collagen expression
in cultured hepatic stellate cells [55]. Potter et al. reported
that the downregulation of 𝛼
1
type I collagen by 1,25(OH)
2
D
3
is mediated by VDR binding to a proximal Sp1 site and a
distal vitaminD response element in the humanCOL1A1 gene
promoter [57]. Notably, a study from Ding et al. revealed
that ligand-activated VDR antagonizes TGF-𝛽1-dependent
transcription of profibrotic genes in hepatic stellate cells
[56]. TGF-𝛽1 changes ligand activated-VDR binding sites
in the genome promoting VDR binding to SMAD3 sites in
the regulatory regions of profibrotic genes, which decreases
SMAD3 occupancy at these sites causing transcriptional
silencing of the genes and inhibiting fibrosis [56].Thus, VDR
ligands limit fibrosis by modulating the tissue response to
TGF-𝛽1. Ito et al. described that a similar mechanism takes
place in renal fibrosis and showed that the C-terminal 𝛼-
helix 12 of the ligand-binding domain of VDR is necessary
for the interaction with SMAD3 and the suppression of TGF-
𝛽 pathway [53]. Furthermore, they designed VDR ligands
that selectively inhibit TGF-𝛽 signaling without activating
VDR-mediated transcription and significantly attenuate renal
fibrosis in mice without hypercalcemic effects [53]. Another
mechanism involved in the inhibition of TGF-𝛽 pathway
by vitamin D analogs in renal fibrosis has been described:
maxacalcitol blocks the autoinduction of TGF-𝛽1 expression
through the recruitment of a complex between VDR and the
SMAD3phosphatase PPM1A to theTGFB1 promoter, causing
SMAD3 dephosphorylation and release from the promoter
and, consequently, attenuating TGFB1 gene expression [54].
Peritoneal dialysis induces changes in mesothelial cells
that are reminiscent of those occurring during EMT, and that
may finally lead to the development of fibrosis. Vitamin D
compounds prevent the progression of peritoneal fibrosis in
mouse and rat models and inhibit the TGF-𝛽1-induced EMT-
like process in human peritoneal mesothelial cells [58, 91].
Thus, a large body of evidence indicates that vitamin D
compounds protect against organ fibrosis in different tissues
by inhibiting EMT and/or TGF-𝛽 profibrotic action.
4. The Transcription Factors SNAIL1 and
SNAIL2 Repress VDR Gene Expression and
Inhibit 1,25(OH)
2
D
3
Action
Cell responsiveness to 1,25(OH)
2
D
3
mainly relays on VDR
expression levels. VDR protein is expressed in almost all nor-
mal human cell types and tissues, and also in cancer cell lines
and tumors of several origins [8, 92]. Remarkably, elevated
VDRexpression is associatedwith high tumor differentiation,
absence of node involvement, and good prognosis in colon
cancer [93–95], with lower tumor grade, late development of
lymph node metastases, and longer disease-free survival in
breast cancer [43, 96–98], and with improved overall survival
in prostate and non-small cell lung cancer and melanoma
[99–101]. However, certain cancer cell lines do not express
VDR and are unresponsive to 1,25(OH)
2
D
3
. Accordingly,
VDR downregulation has been observed in a proportion
of melanomas and colon, breast, lung, and ovarian tumors
[43, 94, 99, 102–104], which may jeopardize the response to
therapy with vitamin D, 1,25(OH)
2
D
3
, or its analogs.
These lines of evidence prompted us to study the mech-
anisms responsible for VDR downregulation in cancer. We
found that SNAIL1 represses the expression of VDR by
binding to three E-boxes in the human 𝑉𝐷𝑅 gene promoter.
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Moreover, SNAIL1 reduces 𝑉𝐷𝑅 RNA half-life [105]. As a
result, SNAIL1 overexpression in human colon cancer cells
blocks the induction of E-cadherin expression and the acqui-
sition of an epithelial phenotype promoted by 1,25(OH)
2
D
3
.
Consequently, 𝛽-catenin is not relocated from the nucleus to
the plasma membrane adherens junctions and the Wnt/𝛽-
catenin signaling remains active. SNAIL1 also abrogates the
inhibitory effect of 1,25(OH)
2
D
3
on cell proliferation and
migration in cultured cells and the antitumoral action of
the 1,25(OH)
2
D
3
analog EB1089 in xenografted mice [105,
106]. Consistently, Knackstedt et al. have shown that the
downregulation of𝑉𝑑𝑟 observed in the colon ofDSS-induced
colitis mouse model is associated with an increase in the
expression of SNAIL1 and its upstream regulator tumor
necrosis factor- (Tnf-) 𝛼 [107].
In addition to SNAIL1, we reported that its family
member SNAIL2 represses𝑉𝐷𝑅 gene expression through the
same E-boxes in the human 𝑉𝐷𝑅 gene promoter and blocks
the induction of an epithelial phenotype by 1,25(OH)
2
D
3
in
human colon cancer cells. Moreover, SNAIL1 and SNAIL2
show an additive repressive effect on 𝑉𝐷𝑅 gene promoter
[108]. Remarkably, SNAIL1 and/or SNAIL2RNAupregulation
was detected in 76% of colon tumors and significantly
correlated with diminished 𝑉𝐷𝑅 RNA expression. Indeed,
the lowest 𝑉𝐷𝑅 RNA levels were observed in those colon
tumors that overexpress both EMT-TFs [95, 105, 108]. We
also showed that SNAIL1 RNA overexpression in colon
tumors diminishes𝑉𝐷𝑅RNA expression in the histologically
normal tissue adjacent to the tumor, suggesting that SNAIL1-
expressing colon cancer cells secrete signals that modulate
VDR expression in neighboring cells [109].
The repression of 𝑉𝐷𝑅 gene by SNAIL factors is not
exclusive to colon cancer. It has been shown that SNAIL1 and
SNAIL2 downregulate𝑉𝐷𝑅 gene expression and abrogate the
antitumoral action of 1,25(OH)
2
D
3
in human osteosarcoma
and breast cancer cells [110, 111]. The two proximal E-boxes
of the human 𝑉𝐷𝑅 gene promoter are conserved in rat and
mouse, while the most distal box is only partially conserved
with one base substitution. Bai et al. found SNAIL1 binding
only to the most proximal E-box of the rat 𝑉𝑑𝑟 promoter
accompanied by deacetylation of histone H3 in samples from
rat intestine and kidney. Accordingly, an inverse correlation
between SNAIL1 and𝑉𝑑𝑟 levels was observed in those tissues
[112]. de Frutos et al. showed that the sustained activation
of SNAIL1 in transgenic mice represses 𝑉𝑑𝑟 gene expression
in osteoblasts. This downregulation blocks the Vdr-mediated
induction of the osteoclast differentiation factor Rankl and
inhibition of osteoprotegerin, a decoy Rankl receptor that
inhibits osteoclastogenesis. Thus, 𝑉𝑑𝑟 gene downregulation
by SNAIL1 in osteoblasts reduces the osteoclast population
due to an impaired osteoclastogenesis. In addition, chromatin
immunoprecipitation assays indicated that 𝑉𝑑𝑟 gene repres-
sion in mouse osteoblasts is mediated by SNAIL1 binding to
the two proximal E-boxes of murine 𝑉𝑑𝑟 promoter [113].
VDR downregulation takes place also and contributes to
E-cadherin loss during the EMT promoted by the proinflam-
matory cytokine TNFSF12 in renal tubular epithelial cells
[114]. Similarly, VDR repression by TNF-𝛼 sensitizes breast
cancer cells to TGF-𝛽1-induced EMT. Of note, 1,25(OH)
2
D
3
treatment protects against TNF-𝛼-induced VDR loss, sup-
presses TGF-𝛽1-promoted increase in the migration capacity
of cultured breast cancer cells, and inhibits lung metastasis in
an orthotopic breast cancer mouse model [43]. Conversely,
theMET induced by the enforced reexpression of the putative
tumor suppressor KLF4 in hepatocellular carcinoma cells was
accompanied by VDR upregulation and an increase in the
inhibitory effect of 1,25(OH)
2
D
3
on cell proliferation. As a
result, KLF4 and VDR protein expression correlate directly
in human hepatocellular carcinoma [115].
Other EMT-TFs such as ZEB1, ZEB2, TWIST1, or E47
have no effect on the expression of human 𝑉𝐷𝑅 gene
promoter in SW480-ADH human colon cancer cells [108].
However, Lazarova et al. reported that ZEB1 binds to two
distal E-boxes in the murine 𝑉𝑑𝑟 promoter and activates its
expression in COS-7 monkey kidney fibroblasts and SW620
human colon cancer cells, but not in human LNCaP prostate
or HCT116 colon cancer cells [116]. Other studies showed
absence of correlation or a significant direct correlation
between ZEB1 and 𝑉𝐷𝑅 RNA expression in colon cancer
[95, 109, 117]. Furthermore, Pen˜a et al. observed that such
direct correlation was stronger in colon tumors with high
level of the transcriptional coactivator p300 [117]. Globally,
these data suggest a cell- and context-dependent positive
regulation of VDR by ZEB1.
5. Conclusions and Perspectives
Cell fate and phenotype are strictly regulated by extracellular
signals. 1,25(OH)
2
D
3
and EMT-TFs have opposite effects on
epithelial cell phenotype and they antagonize each other
(Figure 1). 1,25(OH)
2
D
3
induces epithelial differentiation
while it inhibits the expression of several EMT inducers.
Conversely, expression of key EMT-TFs in epithelial cells pro-
motes the acquisition of a mesenchymal phenotype, which
in the case of SNAIL1 and SNAIL2 is associated with 𝑉𝐷𝑅
gene repression and the blockade of 1,25(OH)
2
D
3
action on
epithelial differentiation. Thus, a double negative feedback
loop operates between 1,25(OH)
2
D
3
and EMT inducers that
may contribute to the complete acquisition of the phenotype
dictated by the extracellular cues. The loop may first amplify
the signal and later stabilize cell fate once the process is
completed. Hence, the balance between 1,25(OH)
2
D
3
/VDR
and SNAIL family of transcription factors determines cell
fate, and its imbalance may explain the reversibility of the
EMT process. Of note, the transition between epithelial
and mesenchymal phenotypes is also governed by similar
double negative feedback loops among EMT-TFs and certain
microRNAs, such as the ZEB/miR-200 and the SNAIL1/miR-
34 regulatory circuits [22, 118–120].
The implication of EMT in cancer progression and organ
fibrosis and the inhibitory effect of 1,25(OH)
2
D
3
on EMT
have opened the possibility of a therapeutic use of VDR ago-
nists against these diseases. However, the downregulation of
VDR expression found in several types of cancer, frequently
associated with advanced stages of the disease, limits the
applicability of vitamin D compounds to prevention in high-
risk populations and treatment in patients at early stages of
tumor progression. In addition, EMT is a transient event dur-
ing tumorigenesis, and it has been proposed that the reverse
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process (MET) is required for the establishment of metastasis
at distant sites [121, 122]. These lines of evidence have led to
controversy about anticancer therapeutic strategies designed
to inhibit EMT, as theymay favor the formation ofmetastases,
and suggest that these therapies may be limited to patients
diagnosed at early stages of the disease to prevent invasion
and dissemination [23]. Nevertheless, vitamin D compounds
as inhibitors of EMTmay be interesting therapeutic agents for
fibrosis-associated pathologies, in which the EMT process is
not reverted and the mesenchymal phenotype is maintained
during disease progression.
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